Platform trial for off-label oncology drugs using comprehensive genomic profiling under the universal public healthcare system: the BELIEVE trial
ConclusionThe BELIEVE trial provides hope for patients with actionable genetic abnormalities by facilitating access to targeted therapies through off-label drug administration. It establishes a regulatory framework and promotes collaboration between industry and academia by expanding organ-specific and cross-organ biomarker-based treatments.
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research
More News: Academia | Cancer | Cancer & Oncology | Clinical Trials | Genetics | Health Insurance | Insurance | Japan Health | Statistics | Study